Harnessing the immune system in glioblastoma
Cet article passe en revue les connaissances concernant les mécanismes d'échappement immunitaire employés par les glioblastomes ainsi que les effets immunologiques des traitements standard, puis décrit les immunothérapies développées récemment (vaccins, lymphocytes CAR-T et inhibiteurs de point de contrôle immunitaire) et analyse les progrès cliniques réalisés
Glioblastoma is the most common primary malignant brain tumour. Survival is poor and improved treatment options are urgently needed. Although immunotherapies have emerged as effective treatments for a number of cancers, translation of these through to brain tumours is a distinct challenge, particularly due to the blood–brain barrier and the unique immune tumour microenvironment afforded by CNS-specific cells. This review discusses the immune system within the CNS, mechanisms of immune escape employed by glioblastoma, and the immunological effects of conventional glioblastoma treatments. Novel therapies for glioblastoma that harness the immune system and their current clinical progress are outlined, including cancer vaccines, T-cell therapies and immune checkpoint modulators.
British Journal of Cancer , article en libre accès, 2018